Silence Therapeutics plc, a London-headquartered drug development company, dealing with the delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, has appointed Alistair Gray as Non-Executive Director of the Company, with immediate effect.
Silence corporate headquarters based at 1 Lyric Square, London.
Gray will also Chair the Audit Committee, Silence said in a press release on Wednesday.
The company – announcing the appointment – noted that he would bring with him a wealth of consultancy and business experience. Having trained as an accountant, his early career was in senior management positions with Unilever and John Wood Group PLC. Alistair was a Director of Arthur Young (now Ernst and Young) Management Consultants and PA Consulting Group. He founded Genesis Consulting and, most recently, Renaissance & Company, a strategic management consultancy working with clients across business and sport, Silence said.
Gray has served as Executive Chairman of the Winning Scotland Foundation and previously served as Chair of British Swimming and British Basketball, leading significant change in both sports. He is currently Chairman of Edrington’s Pension Trustees, responsible for management of a major private pension fund and also Chair of the trading division of John Hogg & Company. Gray chaired the Audit and Remuneration committees of AorTech International PLC and Highland Distillers PLC, as well as the Pension Trustee Board.
Stephen Parker Ph.D. Non-Executive Chairman of Silence Therapeutics, said:
“We are delighted to welcome Alistair to the Board of Silence Therapeutics. His expertise in strategic leadership will be invaluable as we continue to expand our business and seek to deliver value to our shareholders.”